# Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

> **NCT01957956** · EARLY_PHASE1 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 21 (actual)

## Conditions studied

- Giant Cell Glioblastoma
- Glioblastoma
- Gliosarcoma

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT01957956
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11-11
- **Primary completion:** 2016-11-16
- **Final completion:** 2016-11-16
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2023-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01957956

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01957956, "Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01957956. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*